(Q71695803)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7539558%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

title

Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7539558%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

1 reference

R W Geist

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7539558%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

language of work or name

English

0 references

publication date

1 June 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7539558%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7539558%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

volume

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7539558%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7539558%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

page(s)

1016-1021

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7539558%20AND%20SRC:MED&resulttype=core&format=json

Prostate Specific Antigen after External Beam Radiotherapy for Prostatic Cancer: Followup

20 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

Prostate Specific Antigen in the Management of Patients with Localized Adenocarcinoma of the Prostate Treated with Primary Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

The value of serum prostate specific antigen determinations before and after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

Prognostic implications of prostatespecific antigen in patients with locally advanced prostate cancer treated with high energy neutron beam therapy: Preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

Prostate Specific Antigen Levels after Definitive Irradiation for Carcinoma of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

Prospective comparison between serum monoclonal prostate specific antigen and acid phosphatase measurements in metastatic prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

The effect of pelvic radiation therapy on serum levels of prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

Prostatic-specific antigen doubling times in patients with prostate cancer: a potentially useful reflection of tumor doubling time

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980123-X

7 January 2021

10.1016/S0090-4295(99)80123-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7539558%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

1 reference